NCT05997576 - A Study of TG103 Injection in Non-diabetic Overweight or Obesity | Biotech Hunter

Enrollment

675

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

February 17, 2025

Study Completion Date

March 3, 2025

Conditions

Overweight or Obesity

Interventions

DRUG

TG103 22.5 mg

Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

DRUG

Placebo

Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.

Trial Locations (1)

Clinical Trials Information Group, Shijiazhuang

All Listed Sponsors

lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY